Positron Emission Tomography (PET) quantification of GABAA receptors in the brain of fragile X patients

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  D'Hulst, Charlotte ^a   Heulens, Inge ^a   Van Der Aa, Nathalie ^a,b   Goffin, Karolien ^c   Koole, Michel ^c   Porke, Kathleen ^c   Van De Velde, Marc ^c   Rooms, Liesbeth ^a   Van Paesschen, Wim ^c   Van Esch, Hilde ^c   Van Laere, Koen ^c   Kooy, R Frank ^d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FLUMAZENIL;

ADULT; ARTICLE; BRAIN RADIOGRAPHY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FRAGILE X SYNDROME; FRONTAL CORTEX; HUMAN; INTELLIGENCE QUOTIENT; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; QUANTITATIVE ANALYSIS; TEMPORAL CORTEX; THALAMUS; ADOLESCENT; ANIMAL; BRAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FEMALE; METABOLISM; MIDDLE AGED; MOUSE; RADIOGRAPHY;

ADOLESCENT; ADULT; ANIMALS; BRAIN; FEMALE; FLUMAZENIL; FRAGILE X SYNDROME; HUMANS; MALE; MICE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY; RECEPTORS, GABA-A;

EID: 84942036668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131486     Document Type: Article

References (36)

1. D'Hulst C, Kooy RF. Fragile X syndrome: from molecular genetics to therapy. J Med Genet. 2009; 46 (9):577-84. doi:10.1136/jmg.2008.064667 PMID: 19724010.
2. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3nd ed. Baltimore, MA: Johns Hopkins University Press; 2002. p. 3-109.
3. Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B, Tassinari CA, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia. 1999; 40(8):1092-9. PMID: 10448821.
4. Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014; 343(6174):1002-5. doi: 10.1126/science.1245831 PMID: 24578575.
5. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu Rev Pathol. 2012; 7:219-45. doi:10.1146/annurev-pathol-011811-132457 PMID: 22017584.
6. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012; 122(12):4314-22doi:10.1172/JCI63141 PMID: 23202739.
7. Braat S, Kooy RF. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials. Neuropharmacology. 2015; 88:48-54doi:10.1016/j.neuropharm.2014.06.028 PMID: 25016041.
8. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi Z-P, et al. Attenuated sensitivity to neuroactive steroids in g-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA. 1999; 96(22):12905-10. PMID: 10536021.
9. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, et al. International Union of Pharmacology. XV. Subtypes of g-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998; 50(2):291-313. PMID: 9647870.
10. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008; 4(4):256-63 doi:10.1038/nchembio78 PMID: 18327252.
11. Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012; 229(1):244-9. doi:10.1016/j.bbr.2012.01.031PMID: 22285772.
12. Braat S, D'Hulst C, Heulens I, De Rubeis S, Mientjes E, Nelson DL, et al. The GABA Receptor is an FMRP Target with Therapeutic Potential in Fragile X Syndrome. Cell Cycle. 2015. doi:10.4161/15384101.2014.989114.
13. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci. 2011; 33(5):395-403. doi:10.1159/000332884 PMID: 22067669.
14. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010; 30(29):9929-38. doi:10.1523/jneurosci.1714-10.2010 PMID: 20660275.
15. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007; 69(16):1622-34. PMID: 17938373.
16. Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des. 2004; 10(24):2907- 21. PMID: 15379658.
17. Kooy RF, Oostra BA, Willems PJ. Molecular detection of dynamic mutations. In: Adolph KW, editor. Human Genome Methods. Boca Raton, Florida: CRC Press; 1997. p. 23-53.
18. Van Laere K, Bormans G, Sanabria-Bohorquez SM, de Groot T, Dupont P, De Lepeleire I, et al. In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Biol Psychiatry. 2008; 64(2):153-61. doi:10.1016/j.biopsych.2008.01.021 PMID: 18339360.
19. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27(9):1533-9. doi:10.1038/sj.jcbfm.9600493 PMID: 17519979.
20. Salmi E, Aalto S, Hirvonen J, Langsjo JW, Maksimow AT, Oikonen V, et al. Measurement of GABAA receptor binding in vivo with [11C]flumazenil: A test-retest study in healthy subjects. Neuroimage. 2008; 41(2):260-9. doi:10.1016/j.neuroimage.2008.02.035 PMID: 18411060.
21. Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, et al. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: A key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med. 2006; 47(5):740-7. PMID: 16644742.
22. Errijgers V, Kooy RF. Genetic modifiers in mice: The example of the fragile X mouse model. Cytogenet Genome Res. 2004; 105:448-54. PMID: 15237233.
23. Sundaram SK, Chugani HT, Chugani DC. Positron emission tomography methods with potential for increased understanding of mental retardation and developmental disabilities. Ment Retard Dev Disabil Res Rev. 2005; 11(4):325-30. PMID: 16240413.
24. Menold MM, Shao Y, Wolpert CM, Donnelly SL, Raiford KL, Martin ER, et al. Association analysis of chromosome 15 gabaa receptor subunit genes in autistic disorder. J Neurogenet. 2001; 15(3-4):245- 59. PMID: 12092907.
25. Wagstaff J, Knoll JH, Fleming J, Kirkness EF, Martin-Gallardo A, Greenberg F, et al. Localization of the gene encoding the GABAA receptor beta 3 subunit to the Angelman/Prader-Willi region of human chromosome 15. Am J Hum Genet. 1991; 49(2):330-7. PMID: 1714232.
26. Lucignani G, Panzacchi A, Bosio L, Moresco RM, Ravasi L, Coppa I, et al. GABAA receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Neuroimage. 2004; 22(1):22-8. PMID: 15109994.
27. Holopainen IE, Metsahonkala EL, Kokkonen H, Parkkola RK, Manner TE, Nagren K, et al. Decreased binding of [11C]flumazenil in Angelman syndrome patients with GABA(A) receptor beta3 subunit deletions. Ann Neurol. 2001; 49(1):110-3. PMID: 11198279.
28. D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006; 1121(1):238-45. PMID: 17046729.
29. D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009; 1253:176-83. doi:10.1016/j.brainres.2008.11.075 PMID: 19070606.
30. D'Hulst C, Kooy RF. The GABA(A) receptor: A novel target for treatment of fragile X? Trends Neurosci. 2007; 30(8):425-31. PMID: 17590448.
31. Levenga J, de Vrij FMS, Oostra BA, Willemsen R. Potential therapeutic interventions for fragile X syndrome. Trends Mol Med. 2010; 16(11):516-27. doi:10.1016/j.molmed.2010.08.005 PMID: 20864408.
32. Heulens I, Kooy F. Fragile X syndrome: from gene discovery to therapy. Front Biosci. 2011; 16:1211- 32. 3785 [pii].
33. Braat S, Kooy RF. Fragile X syndrome neurobiology translates into rational therapy. Drug Discov Today. 2014; 19(4):510-9. doi:10.1016/j.drudis.2014.01.013 PMID: 24508819.
34. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27(7):370-7. PMID: 15219735.
35. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 Gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011; 3(64):64ra1. 3/64/64ra1 [pii] doi10.1126/scitranslmed.3001708 PMID: 21209411.
36. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. Sci Transl Med. 2012; 4(152):152ra27. doi:10.1126/scitranslmed.3004214.